Book chapter
Chapter 21 - Emerging Epigenetic Therapies: Lysine Acetyltransferase Inhibitors
Epigenetic Cancer Therapy, pp.471-494
Elsevier Inc
2015
DOI: 10.1016/B978-0-12-800206-3.00021-5
Abstract
The lysine N-ɛ-acetylation has emerged as an important regulator of protein function. Over four decades since the discovery of histone acetylation, a majority of proteins involved in diverse cellular functions are now known to be acetylated. This vast acetylome is regulated reversibly by two classes of enzymes known as lysine acetyltransferases (KATs) and lysine deacetylases (KDACs). Aberrant protein acetylation events have been implicated in various malignancies, while the histone acetylation patterns often indicate the severity of the disease. This chapter elucidates the role of lysine acetyltransferases in different pathological conditions, mainly focusing on the advancement in therapeutics selectively targeting KATs.
Details
- Title: Subtitle
- Chapter 21 - Emerging Epigenetic Therapies: Lysine Acetyltransferase Inhibitors
- Creators
- Stephanie Kaypee - Jawaharlal Nehru Centre for Advanced Scientific ResearchSomnath Mandal - Jawaharlal Nehru Centre for Advanced Scientific ResearchSnehajyoti Chatterjee - Jawaharlal Nehru Centre for Advanced Scientific ResearchTapas K. Kundu - Jawaharlal Nehru Centre for Advanced Scientific Research
- Resource Type
- Book chapter
- Publication Details
- Epigenetic Cancer Therapy, pp.471-494
- DOI
- 10.1016/B978-0-12-800206-3.00021-5
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 2015
- Academic Unit
- Iowa Neuroscience Institute; Neuroscience and Pharmacology
- Record Identifier
- 9984303858602771
Metrics
53 Record Views